Search results for "therapy [Encephalitis]"

showing 10 items of 2838 documents

Treatment patterns for metastatic colorectal cancer in Spain

2020

Abstract Purpose The primary aim of this retrospective study was to describe the treatment patterns according to the type of treatment received by patients with metastatic colorectal cancer (mCRC) in Spain. Methods This was a retrospective, observational, multicenter study performed by 33 sites throughout Spain that included consecutive patients aged 18 years or older who had received or were receiving treatment for mCRC. Results At the time of inclusion, of the 873 evaluable patients, 507 (58%) had received two lines, 235 (27%) had received three lines, 106 (12%) had received four lines, and the remaining patients had received up to ten lines. The most frequent chemotherapy schemes were th…

0301 basic medicineMaleCancer ResearchColorectal cancermedicine.medical_treatmentmedicine.disease_causeTargeted therapy0302 clinical medicineFOLFOXAntineoplastic Combined Chemotherapy ProtocolsKRAS/BRAF mutation statusMolecular Targeted TherapyNeoplasm MetastasisCàncerTreatment patternsGeneral MedicineMiddle AgedTreatment OutcomeOncology030220 oncology & carcinogenesisFOLFIRIMetastaticFemaleKRASGuideline AdherenceColorectal NeoplasmsCàncer Pacientsmedicine.drugResearch ArticleProto-Oncogene Proteins B-rafmedicine.medical_specialtyProto-Oncogene Proteins p21(ras)03 medical and health sciencesInternal medicinemedicineHumansAgedRetrospective StudiesClinical practice guidelineChemotherapybusiness.industryRetrospective cohort studymedicine.diseaseColorectal cancerdigestive system diseases030104 developmental biologySpainMutationObservational studybusiness
researchProduct

Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcino…

2018

Abstract In solid tumors, the presence of lymph node–like structures called tertiary lymphoid structures (TLS) is associated with improved patient survival. However, little is known about how TLS develop in cancer, how their function affects survival, and whether they are affected by cancer therapy. In this study, we used multispectral microscopy, quantitative pathology, and gene expression profiling to analyze TLS formation in human lung squamous cell carcinoma (LSCC) and in an experimental model of lung TLS induction. We identified a niche of CXCL13+ perivascular and CXCL12+LTB+ and PD-L1+ epithelial cells supporting TLS formation. We also characterized sequential stages of TLS maturation…

0301 basic medicineMaleCancer ResearchLung Neoplasmsmedicine.medical_treatmentApoptosis03 medical and health sciencesMiceLymphocytes Tumor-InfiltratingAdrenal Cortex HormonesCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsCarcinomaTumor Cells CulturedTumor MicroenvironmentMedicineAnimalsHumansCXCL13Lung cancerSurvival rateAgedCell ProliferationChemotherapyTumor microenvironmentbusiness.industryGene Expression ProfilingCancerGerminal centerMiddle Agedmedicine.diseaseGerminal CenterPrognosisXenograft Model Antitumor Assays3. Good healthMice Inbred C57BLSurvival Rate030104 developmental biologyTertiary Lymphoid StructuresOncologyCancer researchCarcinoma Squamous CellFemalebusinessFollow-Up StudiesCancer research
researchProduct

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

2016

Background:This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6 (mFOLFOX6) in first-line treatment of locally advanced or metastatic colorectal cancer (mCRC).Methods:Patients received 800-mg intravenous necitumumab (day 1; 2-week cycles), followed by oxaliplatin 85 mg m -2, folinic acid 400 mg m -2, and 5-fluorouracil (400 mg m -2 bolus then 2400 mg m -2 over 46 h). Radiographic evaluation was performed every 8 weeks until progression. Primary endpoint was objective response rate.Results:Forty-four patients were enrolled and treated. Objective response rate was 63.6% (95% confidence interval 47.8-77.6); complete response was observed in …

0301 basic medicineMaleCancer ResearchOrganoplatinum CompoundsLeucovorinPhases of clinical researchmedicine.disease_causeGastroenterology0302 clinical medicineadvanced colorectal cancerAntineoplastic Combined Chemotherapy ProtocolsClinical endpointNeoplasm MetastasisNecitumumabModified FOLFOX6Aged 80 and overnecitumumabAntibodies MonoclonalMiddle AgedOxaliplatinTreatment OutcomeOncologyFluorouracil030220 oncology & carcinogenesisFemaleKRASFluorouracilColorectal Neoplasmsmedicine.drugAdultmedicine.medical_specialtyEGFRNeutropeniamodified FOLFOX6Antibodies Monoclonal HumanizedDisease-Free SurvivalProto-Oncogene Proteins p21(ras)03 medical and health sciencesFolinic acidInternal medicinemedicineKRASHumansAdvanced colorectal cancerAgedbusiness.industrymedicine.diseaseSurvival AnalysisSurgeryOxaliplatinCancérologie030104 developmental biologyClinical StudybusinessNecitumumabBritish Journal of Cancer
researchProduct

Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: r…

2020

Magnesium wasting is a frequent side effect of epidermal growth factor receptor (EGFR)-antibody treatment as magnesium-absorption mechanisms are dependent on EGFR signaling. EGFR-inhibition results in decreased renal reabsorption. There is evidence that hypomagnesemia during cetuximab treatment correlates with response. The prognostic role of hypomagnesemia during bevacizumab treatment has not been studied yet. Here, we evaluate the prognostic value of hypomagnesemia in patients with metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab as first-line therapy. A total of 391 of 752 patients of the firstline irinotecan study population had magnesium levels measured a…

0301 basic medicineMaleCancer Researchmedicine.medical_specialtyRenal Tubular Transport Inborn ErrorsBevacizumabSide effectColorectal cancerHypercalciuriaLeucovorinCetuximabIrinotecanGastroenterologyHypomagnesemia03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)MagnesiumAgedRetrospective StudiesPharmacologyCetuximabbusiness.industryHazard ratiomedicine.diseasePrognosisIrinotecanBevacizumabSurvival RateNephrocalcinosis030104 developmental biologyOncology030220 oncology & carcinogenesisFOLFIRICamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugFollow-Up StudiesAnti-cancer drugs
researchProduct

Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.

2020

Abstract Background Elevated lactate dehydrogenase (LDH) is a known predictive and prognostic factor for a poor outcome in patients with metastatic melanoma. It is unclear whether first-line targeted therapy (TT) or immune checkpoint inhibition (ICI) is more beneficial in melanoma patients with elevated LDH because prospective studies in this area are lacking. Methods This multicentre retrospective cohort study was conducted at 25 melanoma centres worldwide to analyse progression-free survival (PFS) and overall survival (OS) among melanoma patients with elevated LDH. The role of confounders was addressed by using inverse probability of treatment weighting. Results Among 173 BRAFV600-mutant …

0301 basic medicineMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentProgrammed Cell Death 1 ReceptorMedizinGastroenterologyTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective cohort studyImmune Checkpoint InhibitorsMelanomaAgedRetrospective Studiesbusiness.industryMelanomaConfoundingRetrospective cohort studyMiddle Agedmedicine.diseasePrognosisImmune checkpoint3. Good healthBlockadeSurvival Rate030104 developmental biologyOncologyCTLA-4030220 oncology & carcinogenesisDrug Therapy CombinationFemaleImmunotherapybusinessFollow-Up StudiesEuropean journal of cancer (Oxford, England : 1990)
researchProduct

The effects of acceptance and commitment therapy on eating behavior and diet delivered through face-to-face contact and a mobile app: a randomized co…

2018

Background Internal motivation and good psychological capabilities are important factors in successful eating-related behavior change. Thus, we investigated whether general acceptance and commitment therapy (ACT) affects reported eating behavior and diet quality and whether baseline perceived stress moderates the intervention effects. Methods Secondary analysis of unblinded randomized controlled trial in three Finnish cities. Working-aged adults with psychological distress and overweight or obesity in three parallel groups: (1) ACT-based Face-to-face (n = 70; six group sessions led by a psychologist), (2) ACT-based Mobile (n = 78; one group session and mobile app), and (3) Control (n = 71; …

0301 basic medicineMaleEmotionsMedicine (miscellaneous)Intuitive eatingravinnonsaantiRegulation of eating behaviormuutosOverweightAcceptance and commitment therapylaw.inventionBody Mass IndexEating0302 clinical medicineRandomized controlled trialBehavior changelawWeight lossSurveys and QuestionnairessääntelyPsychologyPSYCHOLOGICAL TREATMENTS030212 general & internal medicinelcsh:RC620-627Health EducationFinlandtietoinen läsnäolo2. Zero hungerOBESE ADULTSNutrition and DieteticsIntuitive eatinglcsh:Public aspects of medicineBehavior change1184 Genetics developmental biology physiologyylipainoTASTE ATTITUDESMiddle AgedMobile Applications3. Good healthlcsh:Nutritional diseases. Deficiency diseasesInhibition PsychologicalTreatment OutcomemHealthMINDFULNESS-BASED INTERVENTION/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalemedicine.symptomMindfulnessClinical psychologyAdulthyväksymis- ja omistautumisterapiaWEIGHT-LOSSPERCEIVED STRESSPhysical Therapy Sports Therapy and RehabilitationMHealthSelf-Control03 medical and health sciencesCOMPETENCE INVENTORYSDG 3 - Good Health and Well-beingRewardsyöminenmedicineHumansObesityAcceptance and Commitment TherapykäyttäytyminenMotivationPsykologi030109 nutrition & dieteticsbusiness.industryResearchDietary intakelcsh:RA1-1270Feeding BehaviorOverweightmedicine.diseaseObesityACTMindful eatingDietFOOD CRAVINGSPSYCHOMETRIC PROPERTIESPHYSICAL-ACTIVITY416 Food Sciencelihavuus3111 BiomedicinesyömishäiriötbusinessBody mass indexIntuitionThe International Journal of Behavioral Nutrition and Physical Activity
researchProduct

Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro…

2018

BACKGROUND: There currently are no internationally recognised treatment guidelines for patients with advanced gastric cancer/gastro-oesophageal junction cancer (GC/GEJC) in whom two prior lines of therapy have failed. The randomised, phase III JAVELIN Gastric 300 trial compared avelumab versus physician's choice of chemotherapy as third-line therapy in patients with advanced GC/GEJC. PATIENTS AND METHODS: Patients with unresectable, recurrent, locally advanced, or metastatic GC/GEJC were recruited at 147 sites globally. All patients were randomised to receive either avelumab 10 mg/kg by intravenous infusion every 2 weeks or physician's choice of chemotherapy (paclitaxel 80 mg/m2 on days 1, …

0301 basic medicineMaleEsophageal Neoplasmsmedicine.medical_treatmentchemotherapyGastroenterologyChoice Behaviorlaw.invention0302 clinical medicineRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsClinical endpointMedicinePractice Patterns Physicians'Aged 80 and overHazard ratioAntibodies MonoclonalHematologyMiddle AgedPrognosisChemotherapy regimenAdenocarcinoma MucinousSurvival RateOncology030220 oncology & carcinogenesisFemaleImmunotherapyEsophagogastric Junctionmedicine.drugPD-L1Adultmedicine.medical_specialtyAdolescentPaclitaxelAdenocarcinomaAntibodies Monoclonal HumanizedIrinotecanDecision Support Techniquesgastro-oesophageal junction cancer03 medical and health sciencesYoung AdultStomach NeoplasmsInternal medicineGastrointestinal TumorsHumansddc:610Survival rateAgedChemotherapybusiness.industrygastric cancerInternational AgenciesOriginal Articlesphase IIICarcinoma PapillaryClinical trialIrinotecanEditor's Choice030104 developmental biologyavelumabNeoplasm Recurrence LocalbusinessCarcinoma Signet Ring CellBiomarkersFollow-Up Studies
researchProduct

Effectiveness of the physical activity intervention program in the PREDIMED-Plus study: a randomized controlled trial

2018

[Background] The development and implementation of effective physical activity (PA) intervention programs is challenging, particularly in older adults. After the first year of the intervention program used in the ongoing PREvención con DIeta MEDiterránea (PREDIMED)-Plus trial, we assessed the initial effectiveness of the PA component.

0301 basic medicineMaleMediterranean diethumanosrestricción calóricaMyocardial InfarctionMedicine (miscellaneous)physical activitycardiovascular-diseaseejercicio físicoDiet MediterraneanPersones granslaw.inventionmissing data0302 clinical medicineClinical trialsRandomized controlled trialpreventionlawSurveys and QuestionnairesClinical endpoint030212 general & internal medicineolder-adultsStrokeGeneralized estimating equationlcsh:RC620-627mediana edadolder adultsBody mass index2. Zero hungerancianoNutrition and Dieteticssobrepesodietaresultado del tratamientolcsh:Public aspects of medicinehealthMiddle Agedwaist circumference3. Good healthlcsh:Nutritional diseases. Deficiency diseasesTreatment Outcomeestilo de vidaOlder adultsWaist circumferenceFemalewomenpérdida de pesometaanalysisRandomized control trialmedicine.medical_specialtyWaistPes corporalPhysical Therapy Sports Therapy and RehabilitationExercicibody mass indexClinical nutrition03 medical and health sciencesWeight LossmedicineHumansIntervention programObesityLife StyleobesidadExerciseinfarto de miocardioAgedCaloric Restriction030109 nutrition & dieteticsperímetro abdominalbusiness.industrybehaviorPhysical activityResearchíndice de masa corporallcsh:RA1-1270OverweightBody weightmedicine.diseaserandomized control trialDiettamaño de la muestraintervention programSample SizePhysical therapyOlder peoplebusinessBody mass indexAssaigs clínicsInternational Journal of Behavioral Nutrition and Physical Activity
researchProduct

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.

2020

Abstract Ibrutinib, obinutuzumab, and venetoclax demonstrate synergy in preclinical models of mantle cell lymphoma (MCL). OAsIs (NCT02558816), a single-arm multicenter prospective phase 1/2 trial, aimed to determine the maximum tolerated dose of venetoclax in combination with fixed doses of ibrutinib and obinutuzumab, in relapsed MCL patients. At the venetoclax MTD, extension cohorts were opened for relapsed and untreated patients. Safety and efficacy were secondary objectives. Minimal residual disease (MRD) was assessed by allele-specific oligonucleotide quantitative polymerase chain reaction. Between 14 October 2015 and 29 May 2018, 48 patients were enrolled. No dose-limiting toxicity was…

0301 basic medicineMaleNeoplasm Residualmedicine.medical_treatmentImmunoglobulin Variable RegionHematopoietic stem cell transplantationKaplan-Meier EstimateLymphoma Mantle-CellBiochemistryGastroenterologychemistry.chemical_compound0302 clinical medicinePiperidinesObinutuzumabAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesProspective cohort studyAged 80 and overSulfonamidesHematopoietic Stem Cell TransplantationHematologyMiddle AgedCombined Modality TherapyProgression-Free Survival3. Good healthTreatment Outcome030220 oncology & carcinogenesisIbrutinibFemaleImmunoglobulin Heavy Chainsmedicine.medical_specialtyMaximum Tolerated DoseImmunologyAntibodies Monoclonal Humanized03 medical and health sciencesInternal medicinemedicineHumansProgression-free survivalAgedVenetoclaxbusiness.industryAdenineCell Biologymedicine.diseaseBridged Bicyclo Compounds HeterocyclicGenes p53Minimal residual diseaseHematologic Diseases030104 developmental biologychemistryMutationMantle cell lymphomabusinessFollow-Up StudiesBlood
researchProduct

Consumption of sugar-sweetened beverages and artificially sweetened beverages from childhood to adulthood in relation to socioeconomic status – 15 ye…

2018

Background In Norway, social inequalities in health and health-related behaviors have been reported despite the well-developed welfare state. The objective of the present study was to analyze; (i) the development in frequency of consumption of sugar-sweetened beverages (SSB) and artificially sweetened beverages (ASB) from childhood to adulthood; (ii) socioeconomic inequalities in the consumption of SSB and ASB using different indicators of socioeconomic status (SES); (iii) time trends in potential disparities in SSB and ASB consumption among different socioeconomic groups to assess the development in socioeconomic inequality from childhood to adulthood. Methods This study uses data from the…

0301 basic medicineMaleNon-Nutritive SweetenersDietary SugarsMedicine (miscellaneous)Sugar-sweetened beveragesCohort Studies0302 clinical medicineSurveys and QuestionnairesVegetablesMedicine030212 general & internal medicineChildlcsh:RC620-627Nutrition and DieteticsSchoolsNorwaylcsh:Public aspects of medicineTime trendsPeer reviewlcsh:Nutritional diseases. Deficiency diseasesSocioeconomic statuslanguageFemaleAdultAdolescentArtificially sweetened beveragesPhysical Therapy Sports Therapy and RehabilitationNorwegianClinical nutritionBeverages03 medical and health sciencesYoung AdultHumansSocial inequalitySocioeconomic statusConsumption (economics)030109 nutrition & dieteticsTime trendsbusiness.industryResearchRepeated measures designlcsh:RA1-1270Feeding Behaviorlanguage.human_languageDietSocial ClassSocioeconomic FactorsFruitSweetening AgentsLongitudinalbusinessSugarsDemographyFollow-Up StudiesInternational Journal of Behavioral Nutrition and Physical Activity
researchProduct